Literature DB >> 15958605

A novel model for prediction of human drug clearance by allometric scaling.

Huadong Tang1, Michael Mayersohn.   

Abstract

Sixty-one sets of clearance (CL) values in animal species were allometrically scaled for predicting human clearance. Unbound fractions (f(u)) of drug in plasma in rats and humans were obtained from the literature. A model was developed to predict human CL: CL=33.35 ml/min x (a/Rf(u))(0.770), where Rf(u) is the f(u) ratio between rats and humans and a is the coefficient obtained from allometric scaling. The new model was compared with simple allometric scaling and the "rule of exponents" (ROE). Results indicated that the new model provided better predictability for human values of CL than did ROE. It is especially significant that for the first time the proposed model improves the prediction of CL for drugs illustrating large vertical allometry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958605     DOI: 10.1124/dmd.105.004143

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  26 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 2.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Authors:  Mohammad S Alavijeh; Mansoor Chishty; M Zeeshan Qaiser; Alan M Palmer
Journal:  NeuroRx       Date:  2005-10

Review 3.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

4.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.

Authors:  Jie Zhao; Yanguang Cao; William J Jusko
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

5.  Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.

Authors:  Tycho Heimbach; Suresh B Lakshminarayana; Wenyu Hu; Handan He
Journal:  AAPS J       Date:  2009-08-26       Impact factor: 4.009

6.  Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.

Authors:  Ruihong Yu; Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  AAPS J       Date:  2019-07-24       Impact factor: 4.009

7.  Strategy for Extending Half-life in Drug Design and Its Significance.

Authors:  Hakan Gunaydin; Michael D Altman; J Michael Ellis; Peter Fuller; Scott A Johnson; Brian Lahue; Blair Lapointe
Journal:  ACS Med Chem Lett       Date:  2018-04-02       Impact factor: 4.345

8.  Systemic administration of the antioxidant/iron chelator α-lipoic acid protects against light-induced photoreceptor degeneration in the mouse retina.

Authors:  Liangliang Zhao; Chenguang Wang; Delu Song; Yafeng Li; Ying Song; Guanfang Su; Joshua L Dunaief
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-21       Impact factor: 4.799

9.  Modelling and PBPK simulation in drug discovery.

Authors:  Hannah M Jones; Iain B Gardner; Kenny J Watson
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

10.  Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.

Authors:  Zhi-wei Gao; Yun-ting Zhu; Ming-ming Yu; Bin Zan; Jia Liu; Yi-fan Zhang; Xiao-yan Chen; Xue-ning Li; Da-fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.